By Dr. Max Jones and Dr. Gale Bozzo, two professors at UG’s Ontario Agricultural College (Department of Plant Agriculture), October 25thThis license permits the cultivation of psilocybin mushrooms and was one of the first universities to be licensed in Canada.
“We are very excited about this approval. “It will allow us to provide well-characterized, chemically consistent materials for clinical evaluation,” said Jones.He previously obtained a license to study cannabis November 2018 likewise.
According to Jones, there are more than 200 species of mushrooms that can produce psilocybin. “Those species are not that closely related. They are diverse,” Jones said in a press release. “So scientists like me wonder, what else do these mushrooms produce? Given that there are 200 species that produce compounds that affect the human brain, It may also be producing other interesting compounds.”
Psilocybin therapy has become a common treatment for conditions such as depression, addiction, obsessive-compulsive disorder, and post-traumatic stress disorder. According to Professor Melissa Perot, Ontario Veterinary Collegeof Department of Biomedical Science Another researcher involved in this study has a specific feature they’d like to explore. “Many people are already dealing with psilocybin, but I think it’s important to note the potential bioactivity of some of the other compounds found in these mushrooms and their therapeutic value alone or in combination with psilocybin.” I’m interested in whether,” he said Perreault.
Perreault’s experience included studying the molecular and cellular mechanisms associated with conditions such as depression and autism spectrum disorders. Her plan is to examine signaling pathways that psilocybin may affect. “If these compounds have potential therapeutic value, we will incorporate them into some of the models I am working on, such as models used to study certain aspects of depression and autism. We will look at the treatment effect,” she said.
In conclusion, Jones said he believes increased access to mushrooms will allow more research to be conducted. “We really need a public supply of these mushrooms,” said Jones. We aim to create a supply of mushrooms used for preclinical and possibly clinical trials where the genetics and cultivation methodologies are fully disclosed to researchers and the public.
The press release also says the researchers plan to develop synthetic mushroom cultivation methods that can be easily replicated.
Psilocybin mushrooms continue to grow in interest in the medical community. early January of this year, one organization It presented evidence of the mushroom’s therapeutic properties and announced its intention to reschedule this substance in the United Nations Convention on Psychotropic Substances Act of 1971. JAMA Psychiatry showed that psilocybin may treat alcoholism. In mid-September, the University of Copenhagen began investigating the effects of psilocybin in treating obesity. Just last week, Johns Hopkins University released a study analyzing how psilocybin helps patients quit smoking. has also become the muse of many famous musicians.
Oregon plans to finalize rules regulating psilocybin by December 2022, while several other states have put forward psilocybin permits in November ballots.
